Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C7H9N3O |
| Molecular Weight | 151.1659 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)NNC1=CC=CC=C1
InChI
InChIKey=AVKHCKXGKPAGEI-UHFFFAOYSA-N
InChI=1S/C7H9N3O/c8-7(11)10-9-6-4-2-1-3-5-6/h1-5,9H,(H3,8,10,11)
| Molecular Formula | C7H9N3O |
| Molecular Weight | 151.1659 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| [2 cases of acute hemolytic anemia following intake of phenylsemicarbazide. Remarks on poikilocytosis and review of literature]. | 1965-05-01 |
|
| [A case of prolonged phenylsemicarbazide poisoning in an adult; comatose form]. | 1953-06-12 |
|
| [Acute hemolytic anemia caused in infants by the administration of large doses of phenylsemicarbazide]. | 1950-05-30 |
|
| [Acute hemolytic anemia in infants induced by administration of phenylsemicarbazide]. | 1950 |
|
| [Phenylsemicarbazide poisoning: hemolytic anemia with hepatitis: 2 cases]. | 1950 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13082415
hemolytic anemia in human
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:05:16 GMT 2025
by
admin
on
Mon Mar 31 18:05:16 GMT 2025
|
| Record UNII |
1LR2578324
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C2356
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID9020245
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
4169
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
CHEMBL1593719
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
2763
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
203-072-3
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
61002
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
2128
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
SUB09763MIG
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
C72931
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
1LR2578324
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
m396
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | Merck Index | ||
|
103-03-7
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
PHENICARBAZIDE
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
235808
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | RxNorm | ||
|
100000082254
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |